334 related articles for article (PubMed ID: 16417591)
1. Pharmacology of botulinum toxin: differences between type A preparations.
Rosales RL; Bigalke H; Dressler D
Eur J Neurol; 2006 Feb; 13 Suppl 1():2-10. PubMed ID: 16417591
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
[TBL] [Abstract][Full Text] [Related]
3. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
4. [Different botulinum toxins and their specifications].
Beylot C
Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S77-85. PubMed ID: 19576490
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of therapeutic botulinum toxin preparations.
Dressler D; Benecke R
Disabil Rehabil; 2007 Dec; 29(23):1761-8. PubMed ID: 18033601
[TBL] [Abstract][Full Text] [Related]
6. Comparing two botulinum toxin type A formulations using manufacturers' product summaries.
Wenzel R; Jones D; Borrego JA
J Clin Pharm Ther; 2007 Aug; 32(4):387-402. PubMed ID: 17635341
[TBL] [Abstract][Full Text] [Related]
7. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
[TBL] [Abstract][Full Text] [Related]
8. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological aspects of therapeutic botulinum toxin preparations].
Dressler D
Nervenarzt; 2006 Aug; 77(8):912-21. PubMed ID: 16810528
[TBL] [Abstract][Full Text] [Related]
10. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
Vergilis-Kalner IJ
J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
[TBL] [Abstract][Full Text] [Related]
11. The evolution of botulinum neurotoxin type A for cosmetic applications.
Carruthers J; Carruthers A
J Cosmet Laser Ther; 2007 Sep; 9(3):186-92. PubMed ID: 17763029
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
Simonetta Moreau M; Cauhepe C; Magues JP; Senard JM
Br J Dermatol; 2003 Nov; 149(5):1041-5. PubMed ID: 14632812
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.
Wohlfarth K; Kampe K; Bigalke H
Mov Disord; 2004 Mar; 19 Suppl 8():S65-7. PubMed ID: 15027057
[TBL] [Abstract][Full Text] [Related]
14. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
Ranoux D; Gury C; Fondarai J; Mas JL; Zuber M
J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):459-62. PubMed ID: 11909903
[TBL] [Abstract][Full Text] [Related]
15. Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions.
Kranz G; Sycha T; Voller B; Gleiss A; Schnider P; Auff E
Dermatol Surg; 2006 Jul; 32(7):886-90. PubMed ID: 16875469
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin (Botox, Dysport, and Myobloc): pharmacology 101.
Wynn RL
Gen Dent; 2011; 59(2):88-90. PubMed ID: 21903516
[No Abstract] [Full Text] [Related]
17. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
[TBL] [Abstract][Full Text] [Related]
18. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
19. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
Frevert J
Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
[TBL] [Abstract][Full Text] [Related]
20. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.
Dressler D; Hallett M
Eur J Neurol; 2006 Feb; 13 Suppl 1():11-5. PubMed ID: 16417592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
